Kodiak Sciences Inc. (NASDAQ:KOD)
| Market Cap | $6.96B+464.5% |
| Revenue (ttm) | $0 |
| Net Income | -$241.99M-21.1% |
| EPS | -$4.19-10.3% |
| Shares Out | 62.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 222,427.47 |
| Open | $107.90 |
| Previous Close | $108.06 |
| Day's Range | $107.25 - $112.31 |
| 52-Week Range | $18.05 - $112.31 |
| Beta | 2.02 |
| Analysts | Buy |
| Price Target | $115.25(+4.01%) |
| Earnings Date | Nov 12, 2026 |
About KOD
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Kodiak Sciences Inc. Stock Analysis — InsiderScore
Kodiak Sciences Inc. scored higher than 64% of companies evaluated by InsiderBuying, and ranked 21st out of 92 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Kodiak Sciences Inc. bought $181.33 million of stock across 86 purchases in the last 90 days, the largest of them $20.19 million.
The average purchase added about 0% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating KOD in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Nov 12, 2026Earnings report
$KOD stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in KOD holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by KOD's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
KOD Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New KOD patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to KOD from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in KOD
| XBIState Street SPDR S&P Biotech ETF | $141.26M |
| VTIVanguard Morningstar Total Stock Market ETF | $122.34M |
| IWMiShares Russell 2000 ETF | $110.40M |
| IBBiShares Biotechnology ETF | $48.43M |
| VXFVanguard Extended Market ETF | $42.31M |
| IWOiShares Russell 2000 Growth ETF | $40.19M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from KOD’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
-0.1 since Oct 1Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.